Stokes Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
Other funds holding ABBV
Stokes Capital Advisors's ABBV Position: Q3 2026 in Review
Stokes Capital Advisors reduced its AbbVie (ABBV) stake by 4.4% in Q3 2026, selling an estimated $427K and leaving 35,791 shares worth $9.36M. The position accounts for 2.06% of the portfolio, ranked #15.
Stokes Capital Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.43M in Q2 2026. 4,001 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.
- Stokes Capital Advisors held 35,791 shares of AbbVie worth $9.36M as of Q3 2026.
- Stokes Capital Advisors sold 1,665 AbbVie shares in Q3 2026, an estimated $427K.
- AbbVie made up 2.06% of Stokes Capital Advisors's portfolio in Q3 2026, its #15 holding.
- Stokes Capital Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
- Stokes Capital Advisors's AbbVie position peaked at $9.43M in Q2 2026.
- 4,001 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.
Based on Stokes Capital Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.